Compare Crispr Therapeutics AG (CRSP) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Peloton Interactive Inc — how do they compare? Crispr Therapeutics AG trades at $50.3 (market cap $4.97B), while Peloton Interactive Inc trades at $6.38 (market cap $2.67B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Peloton Interactive Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | PTON | |
|---|---|---|
Market Cap | $4.97B | $2.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $9.00 |
52-Week Low | $44.34 | $3.71 |
Enterprise Value | $3.32B | $3.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Peloton (PTON) trades at $6.08, up 3.75% on the day, as technical indicators show a bullish trend with neutral oscillators. The company has achieved a significant turnaround in cash flow, with operating cash flow positive at $333 million in 2025, and is projected to return to net profitability in 2026. However, revenue continues to decline, and the stock carries a high P/E ratio of 101.25, reflecting investor optimism about future earnings despite current challenges. Recent news highlights inclusion in the S&P SmallCap 600 index and leadership changes.
The outlook for PTON hinges on sustaining profitability and reversing revenue declines. Opportunities include strong free cash flow generation and cost-cutting success, but risks involve persistent revenue shrinkage, high debt levels, and intense competition. Analyst consensus is cautiously optimistic with a $7.50 price target, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
